Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.

Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lütgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF.

Nat Biotechnol. 2015 May;33(5):549-554. doi: 10.1038/nbt.3179. Epub 2015 Mar 23.

2.

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.

Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF.

Gut. 2018 Apr;67(4):736-745. doi: 10.1136/gutjnl-2016-312577. Epub 2017 Mar 30.

3.

Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.

Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, Soulier E, Royer C, Thumann C, Mee CJ, McKeating JA, Dragic T, Pessaux P, Stoll-Keller F, Schuster C, Thompson J, Baumert TF.

Gastroenterology. 2010 Sep;139(3):953-64, 964.e1-4. doi: 10.1053/j.gastro.2010.05.073. Epub 2010 Jun 2.

4.

[Claudin 1 as a target for anti-hepatitis C virus strategy].

Fukasawa M.

Yakugaku Zasshi. 2014;134(5):635-40. Review. Japanese.

5.

Anti-hepatitis C virus strategy targeting host entry factor claudin-1.

Fukasawa M.

Uirusu. 2015;65(2):245-254. Review. Japanese.

6.

Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.

Fukasawa M, Nagase S, Shirasago Y, Iida M, Yamashita M, Endo K, Yagi K, Suzuki T, Wakita T, Hanada K, Kuniyasu H, Kondoh M.

J Virol. 2015 May;89(9):4866-79. doi: 10.1128/JVI.03676-14. Epub 2015 Feb 11.

7.

Hepatitis: Tightening the grip on clearing HCV infection.

Ray K.

Nat Rev Gastroenterol Hepatol. 2015 May;12(5):249. doi: 10.1038/nrgastro.2015.55. Epub 2015 Apr 7. No abstract available.

PMID:
25850009
8.

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.

Sautto GA, Wisskirchen K, Clementi N, Castelli M, Diotti RA, Graf J, Clementi M, Burioni R, Protzer U, Mancini N.

Gut. 2016 Mar;65(3):512-23. doi: 10.1136/gutjnl-2014-308316. Epub 2015 Feb 6.

9.

[Anti-hepatitis C Virus Strategy Targeting the Entry Steps].

Fukasawa M.

Yakugaku Zasshi. 2019;139(1):89-95. doi: 10.1248/yakushi.18-00164-5. Review. Japanese.

10.

Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.

Shimizu Y, Shirasago Y, Kondoh M, Suzuki T, Wakita T, Hanada K, Yagi K, Fukasawa M.

J Virol. 2018 Mar 28;92(8). pii: e02258-17. doi: 10.1128/JVI.02258-17. Print 2018 Apr 15.

11.

Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.

Paciello R, Urbanowicz RA, Riccio G, Sasso E, McClure CP, Zambrano N, Ball JK, Cortese R, Nicosia A, De Lorenzo C.

J Gen Virol. 2016 Jan;97(1):82-94. doi: 10.1099/jgv.0.000330. Epub 2015 Oct 29.

12.

Expanding the Host Range of Hepatitis C Virus through Viral Adaptation.

von Schaewen M, Dorner M, Hueging K, Foquet L, Gerges S, Hrebikova G, Heller B, Bitzegeio J, Doerrbecker J, Horwitz JA, Gerold G, Suerbaum S, Rice CM, Meuleman P, Pietschmann T, Ploss A.

MBio. 2016 Nov 8;7(6). pii: e01915-16. doi: 10.1128/mBio.01915-16.

13.

Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.

Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF.

J Hepatol. 2011 Mar;54(3):566-76. doi: 10.1016/j.jhep.2010.10.014. Epub 2010 Nov 11. Review.

14.

A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.

Fofana I, Xiao F, Thumann C, Turek M, Zona L, Tawar RG, Grunert F, Thompson J, Zeisel MB, Baumert TF.

PLoS One. 2013 May 21;8(5):e64221. doi: 10.1371/journal.pone.0064221. Print 2013.

15.

Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection.

Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T.

J Virol. 2009 Feb;83(4):2011-4. doi: 10.1128/JVI.01888-08. Epub 2008 Dec 3.

16.

Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.

Yamashita M, Iida M, Tada M, Shirasago Y, Fukasawa M, Nagase S, Watari A, Ishii-Watabe A, Yagi K, Kondoh M.

J Pharmacol Exp Ther. 2015 Apr;353(1):112-8. doi: 10.1124/jpet.114.217653. Epub 2015 Jan 27.

PMID:
25628391
17.

Hepatitis C virus receptor expression in normal and diseased liver tissue.

Reynolds GM, Harris HJ, Jennings A, Hu K, Grove J, Lalor PF, Adams DH, Balfe P, Hübscher SG, McKeating JA.

Hepatology. 2008 Feb;47(2):418-27.

PMID:
18085708
18.

A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.

Urbanowicz RA, McClure CP, Brown RJ, Tsoleridis T, Persson MA, Krey T, Irving WL, Ball JK, Tarr AW.

J Virol. 2015 Dec 23;90(7):3288-301. doi: 10.1128/JVI.02700-15.

19.

Liver immune-pathogenesis and therapy of human liver tropic virus infection in humanized mouse models.

Bility MT, Li F, Cheng L, Su L.

J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:120-4. doi: 10.1111/jgh.12092. Review.

20.

A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease.

Washburn ML, Bility MT, Zhang L, Kovalev GI, Buntzman A, Frelinger JA, Barry W, Ploss A, Rice CM, Su L.

Gastroenterology. 2011 Apr;140(4):1334-44. doi: 10.1053/j.gastro.2011.01.001. Epub 2011 Jan 13.

Supplemental Content

Support Center